MedImpact-Onco360 Collaboration Addresses Unique Needs of Cancer Care

MedImpact-Onco360 Collaboration Addresses Unique Needs of Cancer Care

<0> MedImpact Healthcare Systems, Inc.Gordon Romanas, 858-790-6475Vice President of MarketingorOnco360, Oncology Pharmacy SolutionsAmvrosios Ioannidis, 646-356-7705Chief Brand & Marketing OfficerM: 516-492-2557 </0>

MedImpact Healthcare Systems, Inc., the nation’s largest privately held provider of pharmacy benefit management (PBM) services, and Onco360, the fastest-growing independent Oncology Pharmacy and Clinical Support Services company, today announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based Oncology pharmaceutical care.

This comprehensive Oncology collaboration is aimed at providing health benefit payers with a proven and effective Oncology Pharmacy program, which combines a cost-efficient dispensing model with clinical excellence.

“The cost of cancer care is projected to increase to nearly $175 billion by 2020,” said Greg Watanabe, President of MedImpact, “That is a four-fold increase in less than 10 years, and one of the biggest reasons why we have been working to develop this solution for our clients.”

Burt Zweigenhaft, CEO of Onco360, stated, “This is an exciting and timely collaboration, as the healthcare industry is at a crossroads and the complexities of cancer care demand a novel solution. By addressing three key facets—fragmentation, coordination of care and cost control—we believe this comprehensive solution can have a positive effect for not just payers, but more importantly, the patients we put at the center of everything we do.”

This collaboration brings the multidisciplinary approach found effective in many of the leading cancer treatment centers to the outpatient setting. The program will feature Board Certified Oncology Pharmacists (BCOP) to provide the highest level of coordination and clinical experience throughout the entire continuum of cancer care, helping improve quality and outcomes while delivering value-based cost controls.

“Bringing together the Oncology experience and expertise of Onco360 with the MedImpact approach to pharmacy benefit management will result in a unique and integrated benefit solution for Oncology. With the coming changes of the Affordable Care Act and the heightened focus on delivering quality measures, it is clear to MedImpact and our clients that something needs to be done to more effectively manage the treatment and cost of cancer care,” said Watanabe.

MedImpact Healthcare Systems, Inc. (), founded in 1989 and headquartered in San Diego, CA, is a PBM that combines subject matter expertise with innovative technology and services to deliver better healthcare outcomes and improve its clients’ positions in the market. MedImpact provides PBM services to 47 million members of health plans, hospitals and employers in the U.S. and abroad. MedImpact’s model is unique: avoiding conflict of interest by deriving revenue from effectively managing client pharmacy benefits rather than dispensing drugs.

MedImpact’s results are quantified through detailed peer analysis, demonstrating how the company can help its clients be market leaders rather than followers

With executive offices in New York City, Onco360 () is the largest independent provider of Oncology Pharmacy Services in the country. Onco360 was founded in 2003 as OncoMed, The Oncology Pharmacy, to serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. In its focus to bring together the stakeholders involved in the cancer treatment process, Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited OncoMed Pharmacies

Suggested Articles

A judge has dismissed the ongoing case between Oscar Health and Blue Cross Blue Shield of Florida over broker arrangements.

Expanding options for dental care in Medicare is a popular idea, but policymakers could take several avenues toward this goal, a new analysis shows.

Tennessee's proposal for a block grant brings a host of questions.